ReviewiMeta2022
The human lung microbiome-A hidden link between microbes and human health and diseases.
Review in iMeta, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Targeting the human gut microbiome: a comparative review of probiotics, prebiotics, synbiotics, and postbiotics.Journal of advanced research · 2026Review
- Dynamic balance of the lung microbiome in health and respiratory diseases.Chinese medical journal · 2026Review
- Study on the correlation between respiratory microbiome alterations and disease location/severity in children with Mycoplasma pneumoniae pneumonia.BMC microbiology · 2026Article
- Circulating tumor-associated biomarkers and pulmonary function in lung cancer patients with comorbid COPD: A retrospective prognostic analysis.Journal of medical biochemistry · 2026Article
- Comparative analysis of the sputum microbiota in different COPD clinical states.Scientific reports · 2026Article
- Respiratory microbiota transplantation: optimized framework and its impact on metabolic and immune characteristics.Chinese medical journal pulmonary and critical care medicine · 2026Article
- Article
- Lung microbiota-mediated biotransformation of mogroside preserves pulmonary barrier integrity and attenuates PMNPJ biofilms and microbiomes · 2026Article
- Bacterial taxa associated with lung cancer cases in Southeast Asians: a pilot case-control study.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- MDPD reveals specific microbial signatures in human pulmonary diseases.Briefings in bioinformatics · 2026Article
- Defining the Critical Role of α-Gustducin for NF-κB Inhibition and Anti-Inflammatory Signal Transduction by Bitter Agonists in Lung Epithelium.International journal of molecular sciences · 2026Article
- Pathogenesis of various pulmonary diseases by tuning immune response: insight from host-microbial crosstalk.Current research in microbial sciences · 2026Review
- Intermittent hypoxia drives lung microbiome-metabolome remodeling to create a pro-inflammatory landscape in murine OSAHS.Frontiers in microbiology · 2026Article
- Oral Microbiome in Oral Cancer Research from Sampling to Analysis: Strategies, Challenges, and Recommendations.Cancers · 2025Review
- Article
- Changes of respiratory microbiota associated with prognosis in pulmonary infection patients with invasive mechanical ventilation-supported respiratory failure.Annals of medicine · 2025Article
- Ferrum@albumin assembled nanoclusters inhibit NF-Acta pharmaceutica Sinica. B · 2025Article
- Disease trajectory and mortality among sepsis patients: a prospective cohort study.BMC infectious diseases · 2025Article
- Airway microbiota and immunity associated with chronic obstructive pulmonary disease severity.Journal of translational medicine · 2025Article
- Sputum Microbiota Compositions Correlate With Metabolome and Clinical Outcomes of COPD-Bronchiectasis Association: A Prospective Cohort Study.Exploration (Beijing, China) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Once thought to be sterile, the human lung is now well recognized to harbor a consortium of microorganisms collectively known as the lung microbiome. The lung microbiome is altered in an array of lung diseases, including chronic lung diseases such as chronic obstructive pulmonary disease, asthma, and bronchiectasis, acute lung diseases caused by pneumonia, sepsis, and COVID-19, and other lung complications such as those related to lung transplantation, lung cancer, and human immunodeficiency virus. The effects of lung microbiome in modulating host immunity and inflammation in the lung and distal organs are being elucidated. However, the precise mechanism by which members of microbiota produce structural ligands that interact with host genes and pathways remains largely uncharacterized. Multiple unique challenges, both technically and biologically, exist in the field of lung microbiome, necessitating the development of tailored experimental and analytical approaches to overcome the bottlenecks. In this review, we first provide an overview of the principles and methodologies in studying the lung microbiome. We next review current knowledge of the roles of lung microbiome in human diseases, highlighting mechanistic insights. We finally discuss critical challenges in the field and share our thoughts on broad topics for future investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.